BioAge Labs (BIOA) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

Platform and scientific approach

• Focused on leveraging human aging biology to develop therapies for metabolic disease using a proprietary discovery platform with over 150 million molecular data points.

• Platform validated by partnerships with Novartis and Lilly for drug and target discovery.

• Longitudinal human aging data tied to outcomes like longevity and chronic diseases underpins target selection.

Lead program: NLRP3 inhibitor (BGE-102)

• BGE-102 is an oral, brain-penetrant NLRP3 inhibitor showing best-in-class CRP reduction in obese patients with elevated CRP, normalizing 93% to healthy levels.

• Achieved 86% reduction in hs-CRP from baseline and strong suppression of IL-1β and IL-6, with favorable safety and tolerability.

• Demonstrated high CNS penetration and a novel, always-available binding site on NLRP3, with published crystal structure.

• Strong IP position with composition of matter protection to 2045 and claims on novel binding sites.

Clinical development and upcoming milestones

• Full phase I data, including multiple dose cohorts, expected in the first half of the year; three-month monotherapy study to start in the second half.

• DME (diabetic macular edema) trial to initiate mid-year, with readout expected mid-next year.

• Cardiovascular focus includes a 50-patient placebo-controlled trial with CRP as the primary endpoint, reading out by year-end.

• Rich biomarker analysis and MRI imaging of the liver included in upcoming studies.